Wuerzburg

• A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous … Ended
  2024-516300-41-00 5 2023-03-07 Multiple Myeloma
• Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af … Ended
  2024-510590-14-00 5 2023-03-03 multiple myeloma
• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 4 2023-02-24 Diffuse Cutaneous Systemic Sclerosis
• Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasth … Ended
  2024-512258-91-00 5 2023-02-03 Generalized Myasthenia Gravis (gMG)
• Pragmatic, randomized, multicentric, double-blind, controlled clinicial trial on the treatment of acute gout attacks with prednisolone versu … Ended
  2024-514738-18-00 6 2023-01-12 gout, acute gout attack
• Efficacy of [18F]florbetaben PET for diagnosis of cardiac AL amyloidosis Ended
  2022-500186-27-00 5 2023-01-11 ATTR Amyloidosis
• Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus I … Ended
  2024-511755-18-00 5 2022-12-23 Invasive Candidiasis/ Candidemia
• A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participant … Ended
  2023-509078-45-00 4 2022-12-19 Multiple sclerosis
• Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhi … Ended
  2022-500652-37-00 4 2022-12-01 Advanced melanoma refractory to prior checkpoint inhibitor therapy
• A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended
  2023-505645-12-00 4 2022-11-28 Parkinson's Disease
• VItamin C in Thermal injuRY: The VICToRY Trial A phase III multi-center randomized trial Ended
  2023-504772-21-00 4 2022-11-22 Severely burned patients
• Safety and efficacy of PC945 (opelconazole) in combination with other antifungal therapy for the treatment of refractory invasive pulmonary … Ended
  2024-511281-36-00 5 2022-11-17 Refractory Invasive Pulmonary Aspergillosis
• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease
• Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission Ended
  2024-512856-40-00 5 2022-09-21 Giant Cell Arteritis
• Early Reperfusion Therapy for Recovery of Vision in Acute Central Retinal Artery Occlusion Ended
  2023-507388-21-00 5 2022-09-08 Acute non-arteritic central retinal artery occlusion (CRAO)
• A multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the rate of weekly lipoprotein apheresis ses … Ended
  2023-508324-35-00 5 2022-08-19 Apheresis
• A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatm … Ended
  2024-513658-31-00 4 2022-08-08 Idiopathic Sudden Sensorineural Hearing Loss
• Epirubicin for the Treatment of Sepsis & Septic Shock Ended
  2024-515776-12-00 4 2022-06-30 Patients with sepsis or septic shock, currently hospitalized at the In
• A Phase I/II Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects with Fab … Ended
  2024-512695-34-00 7 2022-06-28 Fabry Disease (X-linked lysosomal storage disease).
• A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and re … Ended
  2023-507140-37-00 4 2022-06-22 Adult patients with relapsed and refractory multiple myeloma
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid Ended
  2023-508645-40-00 10 2022-05-10 Bullous Pemphigoid (BP)
• A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low … Ended
  2024-514758-65-00 7 2022-05-04 metastatic castration-resistant prostate cancer (mCRPC)
• An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult … Ended
  2024-515832-59-00 5 2022-05-03 Bullous Pemphigoid

Showing 361–384 of 423 trials